UCLA at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
UCLA brings 3 presentations to ASH 2026 in New Orleans. Its program pairs blood cancer care, from CAR T in myeloma to MDS, with iron deficiency in women and pregnancy. It also covers the consequences of abnormal iron delivery from mother to fetus and the changing regulatory environment for new drugs.
| Organization | ASH 2026 Attendance |
|---|---|
UCLA Los Angeles, CA | |
Public research university in Los Angeles, home to the David Geffen School of Medicine. | Symposium Fri Dec 11 11:00am–2:00pm A Case-Based Exploration of CAR T-Cell Therapy in Multiple Myeloma – Where We Are, Where We’re Going Real patient cases showing how experts use approved and investigational CAR-T therapies in multiple myeloma now, and where the treatment is heading. Symposium Fri Dec 11 11:00am–2:00pm Cases and Conversations™: Precision Care in BPDCN—Integrating Updated Diagnostic Pathways With Current and Emerging CD123-Directed Therapies Diagnosing blastic plasmacytoid dendritic cell neoplasm and treating it with drugs aimed at the interleukin-3 receptor, while managing capillary leak syndrome. Symposium Fri Dec 11 3:00pm–6:00pm MDS in the Modern Era: Getting Ahead of the 8-Ball Moving myelodysplastic syndrome care toward early disease-modifying drugs, with hypomethylating agents for higher-risk disease and wider transplant access. Talk Consequences of Maternal Abnormal Iron Delivery to the Fetus How maternal iron deficiency or overload, including in thalassemia, alters placental iron transfer and fetal development, even affecting sex determination. Talk Heavy Menstrual Bleeding, Iron Deficiency, and Iron Deficiency Anemia: A Hidden Epidemic in Plain Sight Heavy menstrual bleeding as the overlooked top cause of iron deficiency in girls and women, and how gynecology and hematology can work together. |
Instantly find 20 buyers from UCLA
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction